Baudax Bio, Inc.
BXRXQ
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 61.45% | 27.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.37% | -13.97% | |||
| Operating Income | -37.37% | 13.97% | |||
| Income Before Tax | 74.10% | 1.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 74.10% | 1.15% | |||
| Earnings from Discontinued Operations | 41.89% | -100.39% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 73.78% | -164.67% | |||
| EBIT | -37.37% | 13.97% | |||
| EBITDA | -34.15% | 13.94% | |||
| EPS Basic | 80.20% | -130.69% | |||
| Normalized Basic EPS | 82.35% | 54.00% | |||
| EPS Diluted | 80.20% | -130.69% | |||
| Normalized Diluted EPS | 82.35% | 54.00% | |||
| Average Basic Shares Outstanding | 63.63% | 110.71% | |||
| Average Diluted Shares Outstanding | 63.63% | 110.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||